Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Around 8% of patients diagnosed with sickle cell disease (SCD) are hepatitis C virus (HCV) carriers. Previously, HCV treatment was seldom considered in SCD patients, as the ribavirin-induced hemolysis and interferon-induced cytopenias could lead to more profound anemia. Nowadays, several oral direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Moussawi, Hassan, Polavarapu, Abhishek D., Asti, Divya, Awada, Zainab, Mulrooney, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244097/
https://www.ncbi.nlm.nih.gov/pubmed/30483041
http://dx.doi.org/10.1159/000493421
_version_ 1783372023072817152
author Al Moussawi, Hassan
Polavarapu, Abhishek D.
Asti, Divya
Awada, Zainab
Mulrooney, Stephen
author_facet Al Moussawi, Hassan
Polavarapu, Abhishek D.
Asti, Divya
Awada, Zainab
Mulrooney, Stephen
author_sort Al Moussawi, Hassan
collection PubMed
description Around 8% of patients diagnosed with sickle cell disease (SCD) are hepatitis C virus (HCV) carriers. Previously, HCV treatment was seldom considered in SCD patients, as the ribavirin-induced hemolysis and interferon-induced cytopenias could lead to more profound anemia. Nowadays, several oral direct-acting antiviral drugs have been developed and approved by the FDA for hepatitis C treatment. While direct-acting antivirals mitigate many of these risks, their safety and efficacy in SCD patients remains insufficiently explored. Here, we report on successfully treating HCV with ledipasvir/sofosbuvir in a compensated cirrhotic patient with SCD and thalassemia minor.
format Online
Article
Text
id pubmed-6244097
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-62440972018-11-27 Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor Al Moussawi, Hassan Polavarapu, Abhishek D. Asti, Divya Awada, Zainab Mulrooney, Stephen Case Rep Gastroenterol Single Case Around 8% of patients diagnosed with sickle cell disease (SCD) are hepatitis C virus (HCV) carriers. Previously, HCV treatment was seldom considered in SCD patients, as the ribavirin-induced hemolysis and interferon-induced cytopenias could lead to more profound anemia. Nowadays, several oral direct-acting antiviral drugs have been developed and approved by the FDA for hepatitis C treatment. While direct-acting antivirals mitigate many of these risks, their safety and efficacy in SCD patients remains insufficiently explored. Here, we report on successfully treating HCV with ledipasvir/sofosbuvir in a compensated cirrhotic patient with SCD and thalassemia minor. S. Karger AG 2018-10-23 /pmc/articles/PMC6244097/ /pubmed/30483041 http://dx.doi.org/10.1159/000493421 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Al Moussawi, Hassan
Polavarapu, Abhishek D.
Asti, Divya
Awada, Zainab
Mulrooney, Stephen
Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title_full Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title_fullStr Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title_full_unstemmed Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title_short Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
title_sort successful treatment of hepatitis c virus by ledipasvir/sofosbuvir in a cirrhotic patient with sickle cell disease and thalassemia minor
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244097/
https://www.ncbi.nlm.nih.gov/pubmed/30483041
http://dx.doi.org/10.1159/000493421
work_keys_str_mv AT almoussawihassan successfultreatmentofhepatitiscvirusbyledipasvirsofosbuvirinacirrhoticpatientwithsicklecelldiseaseandthalassemiaminor
AT polavarapuabhishekd successfultreatmentofhepatitiscvirusbyledipasvirsofosbuvirinacirrhoticpatientwithsicklecelldiseaseandthalassemiaminor
AT astidivya successfultreatmentofhepatitiscvirusbyledipasvirsofosbuvirinacirrhoticpatientwithsicklecelldiseaseandthalassemiaminor
AT awadazainab successfultreatmentofhepatitiscvirusbyledipasvirsofosbuvirinacirrhoticpatientwithsicklecelldiseaseandthalassemiaminor
AT mulrooneystephen successfultreatmentofhepatitiscvirusbyledipasvirsofosbuvirinacirrhoticpatientwithsicklecelldiseaseandthalassemiaminor

Ejemplares similares